Apyx Medical (APYX) Short term Debt (2010 - 2023)

Apyx Medical's (APYX) quarterly Short term Debt came in at $8.9 million in Q2 2023, up 1.3% quarter-over-quarter from $8.8 million in Q1 2023.

Analysis

Apyx Medical (APYX) Short term Debt (2010 - 2023) Analysis & Trends

Apyx Medical (APYX) has reported Short term Debt for 10 consecutive years, with $8.9 million the latest figure, recorded in Q2 2023.

For the quarter ending Q2 2023, Short term Debt changed N/A year-over-year to $8.9 million; the trailing twelve-month figure through Jun 2023 stood at $8.9 million (changed N/A YoY), and the FY2017 full-year result was $239000.0, changed 0.0% from the prior year.
Short term Debt rose to $8.9 million in Q2 2023 per APYX's latest filing, from $8.8 million in the prior quarter.
Across five years, Short term Debt topped out at $8.9 million in Q2 2023 and bottomed at $8.8 million in Q1 2023.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	180.77 Bn	175.17 Bn	7.27 Bn
2	Intuitive Surgical	127.65 Bn	122.43 Bn	1.96 Bn
3	Medtronic	117.15 Bn	108.33 Bn	6.34 Bn
4	Stryker	104.21 Bn	100.73 Bn	4.50 Bn
5	Boston Scientific	63.46 Bn	62.92 Bn	3.85 Bn
6	Edwards Lifesciences	49.73 Bn	45.48 Bn	1.35 Bn
7	Alcon	33.01 Bn	31.56 Bn	1.68 Bn
8	Dexcom	32.17 Bn	30.22 Bn	830.00 Mn
9	Steris	20.72 Bn	20.24 Bn	684.20 Mn
10	Apyx Medical	130.67 Mn	103.06 Mn	8.87 Mn

Historic Data

Download Data